Study S001459

The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02473809
Acronym: LIRABONE
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 60
Start: 2015-08
Primary completion: 2017-10
Lead sponsor: University of Aarhus
Conditions: Diabetes Complications; Osteoporosis
Interventions: DRUG:Liraglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Change in collagen I cross-linked C-terminal telopeptide measured in serum [Days 0, 7, 28, 90, 180]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010756	Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials. Su B, Endocrine	2015	Systematic review	PMID 25074632 DOI	registry reference BACKGROUND:25074632
R0026743	GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia. Nuche-Berenguer B, The Journal of endocrinology	2011	Preclinical	PMID 21372151 DOI	registry reference BACKGROUND:21372151
R0024570	The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Yamada C, Endocrinology	2008	Preclinical	PMID 18039776 DOI	registry reference BACKGROUND:18039776